{"id":"W4403673251","doi":"10.1212/nxi.0000000000200328","title":"Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies","year":2024,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Sanofi Genzyme; Mitsubishi Tanabe Pharma Corporation; Fondation Charcot; Univerzita Karlova v Praze; Karadeniz Teknik Üniversitesi; Eisai; Sanofi; Multiple Sclerosis International Federation; Canadian Institutes of Health Research; Fonds Wetenschappelijk Onderzoek; Murdoch University; Multiple Sclerosis Australia; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Všeobecná Fakultní Nemocnice v Praze; Biogen; Celgene; Hunter New England Local Health District; Sveučilište u Zagrebu; F. Hoffmann-La Roche; Medicinski Fakultet, Sveučilište u Zagrebu; Monash University; Alexion Pharmaceuticals; Vlaamse regering; National Multiple Sclerosis Society; Amicus Therapeutics; Medical Research Council; Teva Pharmaceutical Industries; Novartis Pharma; European Commission","keywords":"Ocrelizumab; Medicine; Disease; Multiple sclerosis; Pregnancy; Internal medicine; Immunology; Rituximab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005414733,0.0001463449,0.0002235971,0.0004398295,0.0002864409,0.0003490524,0.0002477182,0.0002847112,0.0008475262],"category_scores_gemma":[0.002283266,0.0002178583,0.0002595564,0.0006193949,0.0002036082,0.0001959884,0.0002270079,0.0003504902,0.000159303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002685005,"about_ca_system_score_gemma":0.0002537794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004758195,"about_ca_topic_score_gemma":0.003375883,"domain_scores_codex":[0.9996459,0.0001097925,0.0000405199,0.00007495387,0.00005906088,0.00006969009],"domain_scores_gemma":[0.9993122,0.0001447279,0.0003829264,0.00004634517,0.00004473639,0.0000690838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000145984,0.00001906375,0.9980487,0.000005465176,0.00001348546,0.0002291761,0.00006896639,0.00001131849,0.00009278389,0.00000752272,0.00004576197,0.001311704],"study_design_scores_gemma":[0.00001017302,0.0001518326,0.9974262,0.00001350932,0.00003502888,0.001663183,0.0002361701,0.0001369449,0.00009642293,0.00001731023,0.0002104623,0.000002794524],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989237,0.0002936297,0.00003812843,0.00003278049,0.000004551513,0.000008590618,0.0002437434,0.000002466291,0.0004523364],"genre_scores_gemma":[0.9994049,0.00022794,0.00007003915,0.00001976578,0.000005846877,0.0000113107,0.0001575753,0.00000104438,0.0001015042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004758195,"threshold_uncertainty_score":0.009461045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04454560062272642,"score_gpt":0.2798303811565144,"score_spread":0.235284780533788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}